MUC1 and Glycan Probing of CA19-9 Captured Biomarkers from Cyst Fluids and Serum Provides Enhanced Recognition of Ovarian Cancer

Overview

Journal Sci Rep

Date 2025 Jan 25

PMID 39863644

Authors

Shamima Afrin Ruma

Rufus Vinod

Shruti Jain

Kaisa Huhtinen

Johanna Hynninen

Janne Leivo

Kim Pettersson

Karin Sundfeldt

Kamlesh Gidwani

Affiliations

Soon will be listed here.

Abstract

Glycosylation changes of circulating proteins carrying the CA19-9 antigen may offer new targets for detection methods to be explored for the diagnosis of epithelial ovarian cancer (EOC). Search for assay designs for targets initially captured by a CA19-9 antigen reactive antibody from human body fluids by probing with fluorescent nanoparticles coated with lectins or antibodies to known EOC associated proteins. CA19-9 antigens were immobilized from ascites fluids, ovarian cyst fluids or serum samples using monoclonal antibody C192 followed by probing of carrier proteins using anti-MUC16, anti-MUC1 and, anti STn antibodies and seven lectins, all separately coated on nanoparticles. Compared to reference CA19-9 and CA125 immunoassays, nanoparticle aided detection using MUC16, Ma695 and STn antibodies and lectin WGA provided, both separately and combined, improved discrimination of EOC and borderline cancers from benign samples when applied to 60 cyst fluid specimens. When applied to a panel of 44 serum samples (EOC N = 24, healthy and benign samples N = 20) two assays, CA19-9 and CA19-9, stood out with equally superior separations (p-values < 10) of the two groups compared to conventional CA19-9 immunoassay (p-value 0.03).Eu -NP based CA19-9, CA19-9, CA19-9 and CA19-9 show promise for improved EOC detection when applied to ascites & cyst fluids. When applied to circulation-derived samples, the two MUC1 based assays, CA19-9 and CA19-9 outperformed other assay constructs. Our results call for further validation in larger EOC cohorts preferentially with early stage ovarian cancers and all major histotypes against commonly occurring benign conditions.

References

Chen F, Shen J, Wang J, Cai P, Huang Y . Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. Cancer Manag Res. 2018; 10:1313-1318. PMC: 5968799. DOI: 10.2147/CMAR.S155693. View

Ricardo S, Marcos-Silva L, Valente C, Coelho R, Gomes R, David L . Mucins MUC16 and MUC1 are major carriers of SLe(a) and SLe(x) in borderline and malignant serous ovarian tumors. Virchows Arch. 2016; 468(6):715-22. DOI: 10.1007/s00428-016-1929-6. View

Doubeni C, Doubeni A, Myers A . Diagnosis and Management of Ovarian Cancer. Am Fam Physician. 2016; 93(11):937-44. View

Bayoumy S, Hyytia H, Leivo J, Talha S, Huhtinen K, Poutanen M . Glycovariant-based lateral flow immunoassay to detect ovarian cancer-associated serum CA125. Commun Biol. 2020; 3(1):460. PMC: 7442799. DOI: 10.1038/s42003-020-01191-x. View

Lertkhachonsuk A, Buranawongtrakoon S, Lekskul N, Rermluk N, Wee-Stekly W, Charakorn C . Serum CA19-9, CA-125 and CEA as tumor markers for mucinous ovarian tumors. J Obstet Gynaecol Res. 2020; 46(11):2287-2291. PMC: 7693209. DOI: 10.1111/jog.14427. View

Gidwani K, Kekki H, Terava J, Soukka T, Sundfeldt K, Pettersson K . Nanoparticle-aided glycovariant assays to bridge biomarker performance and ctDNA results. Mol Aspects Med. 2019; 72:100831. DOI: 10.1016/j.mam.2019.11.001. View

Engelen M, de Bruijn H, Hollema H, ten Hoor K, Willemse P, Aalders J . Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. Gynecol Oncol. 2000; 78(1):16-20. DOI: 10.1006/gyno.2000.5811. View

Saldova R, Struwe W, Wynne K, Elia G, Duffy M, Rudd P . Exploring the glycosylation of serum CA125. Int J Mol Sci. 2013; 14(8):15636-54. PMC: 3759877. DOI: 10.3390/ijms140815636. View

Tang H, Partyka K, Hsueh P, Sinha J, Kletter D, Zeh H . Glycans related to the CA19-9 antigen are elevated in distinct subsets of pancreatic cancers and improve diagnostic accuracy over CA19-9. Cell Mol Gastroenterol Hepatol. 2016; 2(2):201-221.e15. PMC: 4792034. DOI: 10.1016/j.jcmgh.2015.12.003. View

10.

Safi F, Schlosser W, Kolb G, Beger H . Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J Gastrointest Surg. 1997; 1(2):106-12. DOI: 10.1016/s1091-255x(97)80097-2. View

11.

Islam M, Syed P, Dhondt B, Gidwani K, Pettersson K, Lamminmaki U . Detection of bladder cancer with aberrantly fucosylated ITGA3. Anal Biochem. 2021; 628:114283. DOI: 10.1016/j.ab.2021.114283. View

12.

Wang Y, Sundfeldt K, Mateoiu C, Shih I, Kurman R, Schaefer J . Diagnostic potential of tumor DNA from ovarian cyst fluid. Elife. 2016; 5. PMC: 4946896. DOI: 10.7554/eLife.15175. View

13.

Corfield A, Berry M . Glycan variation and evolution in the eukaryotes. Trends Biochem Sci. 2015; 40(7):351-9. DOI: 10.1016/j.tibs.2015.04.004. View

14.

Petri A, Simonsen A, Hogdall E, Christensen I, Kjaer S, Yip C . Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis. Proteomics Clin Appl. 2010; 4(3):304-14. DOI: 10.1002/prca.200900042. View

15.

Terava J, Tiainen L, Lamminmaki U, Kellokumpu-Lehtinen P, Pettersson K, Gidwani K . Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma. PLoS One. 2019; 14(7):e0219480. PMC: 6658058. DOI: 10.1371/journal.pone.0219480. View

15.

Morya V, Kumari S, Kim E . Virtual screening and evaluation of Ketol-Acid Reducto-Isomerase (KARI) as a putative drug target for Aspergillosis. Clin Proteomics. 2012; 9(1):1. PMC: 3298717. DOI: 10.1186/1559-0275-9-1. View

16.

Salminen L, Nadeem N, Rolfsen A, Dorum A, Laajala T, Grenman S . Exploratory Analysis of CA125-MGL and -STn Glycoforms in the Differential Diagnostics of Pelvic Masses. J Appl Lab Med. 2020; 5(2):263-272. DOI: 10.1093/jalm/jfz012. View

17.

Jain S, Nadeem N, Ulfenborg B, Makela M, Ruma S, Terava J . Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer. Int J Cancer. 2022; 151(7):1175-1184. PMC: 9546485. DOI: 10.1002/ijc.34111. View

18.

Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C . Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021; 397(10290):2182-2193. PMC: 8192829. DOI: 10.1016/S0140-6736(21)00731-5. View

19.

Saldova R, Wormald M, Dwek R, Rudd P . Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Dis Markers. 2009; 25(4-5):219-32. PMC: 3827796. DOI: 10.1155/2008/601583. View